The post compares Q1 2026 results of Eli Lilly and Johnson & Johnson, highlighting Lilly's GLP-1-driven growth and JNJ's portfolio strength, with both raising guidance.
Finnhub07/05, 01:00 AM
Related assets
Coming up for LLY
Explore next
Latest LLY news
Jin1008/17, 07:48 PM
Bloomberg08/13, 05:57 PM
FirstSquawk08/13, 12:08 PM
Berenberg raises Eli Lilly price target to $1,220 from $1,135.